Navigation Links
Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001,at American Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass., April 13, 2007 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced today that results of preclinical studies with its lead product candidate, XMT-1001, will be presented in two posters at the 2007 Annual Meeting of the American Association of Cancer Research (AACR) taking place April 14-18th in Los Angeles, CA. Full text of the abstracts can be viewed online at the AACR website at http://www.AACR.org.

The presentation schedule is as follows:

Abstract #781 "XMT-1001, a novel polymeric prodrug of camptothecin, is a potent inhibitor of LS174 and A2780 human tumor xenografts in a mouse model" will be presented in a poster session on Sunday, April 15th from 8:00 am - 12:00 pm. Alex Yurkovetskiy and Russell C. Petter are the presenting authors.

Abstract #4723 "Pharmacokinetics of a novel camptothecin conjugate (XMT- 1001) in the rat and dog" will be presented in a poster session on Tuesday, April 17th from 1:00 - 5:00 pm. Ullrich Schwertschlag and Alex Yurkovetskiy are the presenting authors.

About XMT-1101

XMT-1001 is Mersana's most advanced Fleximer(R)-based product candidate. It utilizes a novel, dual release mechanism to liberate a camptothecin prodrug, which is then converted within cells into camptothecin, a DNA topoisomerase I inhibitor. In preclinical studies, XMT-1001 was better tolerated and more efficacious than either camptothecin or irinotecan in models of human cancer, showing extended plasma half-life and high concentrations in tumor tissue.

About Fleximer Technology

Fleximer(R) technology improves the therapeutic index of cytotoxic compounds useful as anti-cancer agents by uniquely combining biodegradability with "biological stealth" properties, making Fleximer(R) materials and their conjugates long-circulating and non-immunotoxic. Fleximer(R) molecules are characterized
'"/>




Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/24/2014)... Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty ... for the second quarter ended June 30, 2014. ... $6.5 million in the second quarter of 2014, an increase ... Total revenues of $13.3 million for the six months ended ... period in 2013 , Total revenues generated from the ...
(Date:7/24/2014)... ATLANTA , July 24, 2014  Alimera Sciences, ... company that specializes in the research, development and commercialization ... release its second quarter of fiscal year 2014 financial ... 2014. An investor conference call will follow on the ... The conference call will be hosted by Dan ...
(Date:7/24/2014)... BUFFALO, N.Y. , July 24, 2014  Kinex ... US FDA for the Company,s KX2-391 Ointment for the ... keratosis. This is the Company,s third IND to be ... months. KX2-391 is a synthetic, orally active ... and tubulin polymerization. KX2-391 promotes the induction of p53, ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Alimera Sciences To Release Second Quarter 2014 Results 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4
... Asthmatx, Inc. presented the results of a series ... thermoplasty delivered by the Alair® System, and how this ... in a poster at the 2009 Annual Meeting of ... in Miami Beach, Fla. , The poster, titled "Where ...
... PALO ALTO, Calif., Nov. 9 Women,s sexual health company, ... as it prepares for a 2010 launch of its Viveve ... a name that we believe captures the essence of our ... president and chief executive. "Viveve exists for the sole purpose ...
Cached Medicine Technology:Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting 2Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting 3Women's Sexual Health Company Changes Name in Preparation for Market Entry 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 iTanSmart is ... and iPads. The app provides a tailored approach to ... potentially dangerous sunburns and skin damage. In his review, ... sounds, and capabilities of iTanSmart. , Eaton begins ... app as a ‘better organized’ and ‘great alternative’ to ...
(Date:7/25/2014)... According to the Liver Cirrhosis ... Vkool.com, this is a comprehensive guide that provides ... safe remedies for liver cirrhosis . This ...     Chapter 1: Liver Cirrhosis Bible & ... About Liver Basics ,     Chapter 3: Getting ...
(Date:7/25/2014)... July 25, 2014 At World T.E.A.M. ... July 19, 17 participating developmentally-disabled teens and young adults ... if off-road bicycling, canoeing and hiking can be challenging. ... at the scenic Chesapeake and Ohio Canal National ... athletes both disabled and able-bodied. Under slightly overcast skies ...
(Date:7/24/2014)... 2014 Dr. Henry H. Ting, a ... has been appointed senior vice president and chief quality ... his new role, he will oversee the hospital's clinical ... successfully led quality initiatives and interprofessional teams at the ... for the Door-to-Balloon Alliance, a collaboration of more than ...
(Date:7/24/2014)... bearing human breast tumors, exposure to dim light at ... drug tamoxifen, according to data published in Cancer ... Cancer Research. The negative effects of dim light exposure ... melatonin supplement during the night. , "Resistance to tamoxifen ... breast cancer," said Steven M. Hill, PhD, professor of ...
Breaking Medicine News(10 mins):Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 2Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 3Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 3Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 2Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 3Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2
... Jenifer Goodwin HealthDay Reporter , THURSDAY, Nov. ... known as "K2" is sending young people to the ... toxicologists warn. In recent months, physicians and toxicologists ... emergency rooms after smoking synthetic marijuana. Despite the side ...
... calculations in the supercomputer MareNostrum at the Barcelona Supercomputing ... for Research in Biomedicine (IRB Barcelona) have presented the ... this new database holds more than 1,700 proteins and ... has been developed to study the basic biology of ...
... Nov. 11 (HealthDay News) -- Long-term use of vitamin E ... in men, a new study finds. "An estimated 20.5 ... some evidence of age-related cataract," wrote study author William G. ... in Boston, and colleagues, in a news release. Because ...
... , THURSDAY, Nov. 11 (HealthDay News) -- Many U.S. ... dinner, meals that provide nutrients critical to youngsters, development, ... The American Dietetic Association Foundation poll of 1,193 ... found that breakfast is sometimes missed by 42 percent ...
... American Society of Nephrology (ASN) proudly highlight the ... The Halpin Foundation-ASN Research Grant, created to help ... provides recipients transition funding toward successful application for ... (McGill University Faculty of Medicine), the 2008 recipient ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... depicting emaciated lung cancer patients, a dead body in a ... of secondhand smoke) and other consequences of smoking that will ... people into quitting the habit or not starting in the ...
Cached Medicine News:Health News:'Fake Marijuana' Users Showing Up in Emergency Rooms 2Health News:'Fake Marijuana' Users Showing Up in Emergency Rooms 3Health News:Scientists at IRB Barcelona and BSC publish the world's largest video data bank of proteins 2Health News:Study Finds Vitamins E and C Don't Reduce Cataract Risk in Men 2Health News:Many Kids Skipping Meals, Snacking Instead 2Health News:Putting the spotlight on membranous nephropathy 2Health News:FDA Proposes Graphic Warnings on Cigarette Packs 2Health News:FDA Proposes Graphic Warnings on Cigarette Packs 3
... is a basic laboratory system for pH ... can be obtained when used with a ... • Fast and easy one and two-point ... five buffers (pH 1.68, 4.00, 7.00, 10.01 ...
... Multimode Detectors provide unmatched value and ... and automation needs. Capable of performing ... the same instrument, the DTX Series ... can be integrated seamlessly with Beckman ...
... is a dual-monochromator, multi-detection microplate reader ... 6-384 microplate reading capability. Detection modalities ... intensity (FI) and have optical performance ... or spectrophotometer. Endpoint, kinetic, spectrum and ...
... microplate reader combines improved flexibility ... with a wide range of ... the flexibility, sensitivity and high ... is the ideal detection solution ...
Medicine Products: